ArticleNature communications2026
Generation of GPC-3-targeted radicals for precise therapy of hepatocellular carcinoma.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Exogenous free radicals oxidize and damage tumor proteins, but their non-specific reactivity also causes unintended harm to tumor-suppressive proteins, which compromises the therapeutic efficacy. Here we show a nanosystem that generates in-situ radical-conjugated species with predefined targeting capability toward oncogenic protein. This nanosystem consists of lipid nanoparticles encapsulating polyphenolic tannic acid and hydrophobic calcium peroxide nanoparticles in spatially segregated compartments. Upon cellular uptake, the components are released into the cellular membrane through membrane fusion. Consequently, calcium peroxide nanoparticles act as oxidizing agents, radicalizing tannic acid, which generates gallic acid species conjugated with phenoxyl radicals. Since gallic acid confers specific binding affinity for the oncogenic GPC-3 protein in hepatocellular carcinoma, the radical-conjugated species integrate dual functionalities: a targeting module that binds to the oncogenic GPC-3 protein, and a stabilized phenoxyl radical inducing site-specific oxidative damage. These species direct to GPC-3 and induce localized disruption of critical peptide segments and lipid domains, triggering protein cleavage and membrane shedding, which suppresses downstream signaling including the canonical Wnt/β-catenin pathway and finally inhibits hepatocellular carcinoma progression. By enabling site-specific radical delivery, this strategy achieves precise inactivation of predefined oncogenic targets and establishes a framework for molecularly free-radical-mediated antitumor therapy.
Indexed as
Identifiers
42850232What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.